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Amsterdam, the Netherlands; and New York, New YorkObjectives This study sought to investigate the prognostic value of access site bleeding (ASB) and
non-ASB for recurrent ischemic outcomes and mortality in patients with ST-segment elevation
myocardial infarction (STEMI).
Background The prognostic value of ASB-related complications after STEMI is subject to debate.
Methods The prognostic value of ASB and non-ASB for 1-year mortality, recurrent myocardial
infarction (MI), stent thrombosis, and stroke was investigated in 2,002 STEMI patients undergoing
primary percutaneous coronary intervention. In addition, we performed a meta-analysis of studies
investigating the prognostic value of ASB and non-ASB in patients undergoing percutaneous coronary
intervention.
Results Seventy-four patients (3.7%) were treated by radial access. ASB developed in 124 patients
(6.3%) and non-ASB developed in 102 (5.2%). By multivariable analysis, ASB was not associated with a
higher risk of 1-year mortality (hazard ratio [HR]: 1.03; p ¼ 0.89), recurrent MI (HR: 1.16; p ¼ 0.64), stent
thrombosis (HR: 0.55; p ¼ 0.42), or stroke (HR: 0.47; p ¼ 0.31). Non-ASB was independently associated
with 1-year mortality (HR: 2.77; p < 0.001) and stent thrombosis (HR: 3.10; p ¼ 0.021), but not with
recurrent MI and stroke. In a meta-analysis including 495,630 patients, non-ASB was associated with a
greater adjusted risk of subsequent 1-year mortality than ASB (HR: 1.66; 95% CI: 1.56 to 1.76 and HR:
1.21; 95% CI: 1.11 to 1.31).
Conclusions In STEMI, ASB was not signiﬁcantly associated with 1-year clinical outcomes, whereas
non-ASB was signiﬁcantly associated with 1-year mortality and stent thrombosis. These results taken
together with those of previous studies indicate a greater risk of subsequent mortality in patients with
non-ASB. (J Am Coll Cardiol Intv 2014;7:622–30) ª 2014 by the American College of Cardiology
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623Bleeding complications after percutaneous coronary in-
tervention (PCI) are associated with an increased risk
of mortality and morbidity (1–4). Therefore, considerable
effort has been made to develop novel treatment strategies
directed at minimizing bleeding complications. One such
strategy, performing PCI via the radial artery, has been
shown in prospective, randomized trials to result in a
reduction in bleeding complications arising at the arterial
puncture site (5,6). Unfortunately, although access site
bleeding (ASB) represents a common source of bleeding
in patients undergoing PCI, as many as 50% to 60% of
major or minor bleeding complications originate at a site
not related to the arterial access site (non-ASB) (7–10).
Furthermore, ASB was shown in some studies to be asso-
ciated with increased mortality after PCI, whereas others
have failed to conﬁrm these ﬁndings (7–9,11,12). Moreover,
in the RIVAL (RadIal Vs femorAL access for coronary
intervention) trial, the reduction in ASB did not translate into
a reduction in mortality (5). Therefore, it is of paramount
interest to investigate whether ASB signiﬁcantly affects the
prognosis of patients undergoing PCI because a reduction in
ASB may or may not affect long-term prognosis. In this
study, we investigate the impact of ASB and non-ASB on
discontinuation of antiplatelet therapy and subsequent 1-year
clinical outcomes in patients with ST-segment elevation
myocardial infarction (STEMI) undergoing primary PCIFigure 1. Flow Chart of Search Strategy
Flow chart demonstrating the search strategy and selection of eligible studies
for the meta-analysis.(PPCI). In addition, we perform a meta-analysis of current
literature to assess the prognostic impact of ASB and non-
ASB on 1-year mortality in patients undergoing PCI.
Methods
Source population and procedures. The data analyzed in
this study were obtained from consecutive STEMI pa-
tients who were accepted for PPCI at the Academic
Medical Center–University of Amsterdam between
January 1, 2003 and July 31, 2008. The study complied
with the Declaration of Helsinki, and the local ethics com-
mittee approved the study protocol. In general, patients
qualiﬁed for PPCI if they had typical ischemic chest pain
and at least 1-mm ST-segment elevation in 2 contiguous
leads, a new left bundle-branch block, or a true posterior
myocardial infarction (MI). The PPCI and adjunctive
pharmacological treatment were performed according topump
IQR = interquartile range
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PPCI = primary percutaneous
coronary intervention
STEMI = ST-segment
elevation myocardial
infarctionAmericanCollege of Cardiology/
American Heart Association and
European Society of Cardiology
guidelines. Patients received a
standard 300- to 600-mg loading
dose of clopidogrel. If a coronary
stent was implanted, clopidogrel
was prescribed for at least 1
month in patients with a bare-
metal stent and for 6 to 12
months in patients with a drug-
eluting stent. Patients were
routinely pretreated with 300 mg
aspirin and 5,000 IU unfractio-
nated heparin. An additional
heparin bolus was administered
at the catheterization laboratory,
if necessary, to achieve a targeted
activated clotting time of 300 s followed by an infusion of 12
U/kg/h with titration to achieve a target activated partial
thromboplastin time (aPTT) of 1.5 to 2 times the control.
Glycoprotein IIb/IIIa inhibitors were used at the discretion
of the operator.
Procedural and angiographic data were prospectively
collected in a dedicated database by interventional cardiol-
ogists and specialized nurses. Chart review for consecutive
STEMI patients with available aPTT measurements was
performed in the context of a study designed to investigate
the relationship between periprocedural aPTT and clinical
outcome in STEMI patients treated with PPCI. A detailed
description of the study protocol was previously reported
(13). Laboratory measurements (including hemoglobin) that
were performed in referring hospitals were added to the
study database. We obtained clinical history and detailed
information on periprocedural treatment from inpatient re-
cords in the PCI center and referring hospitals. We obtained
Table 1. Clinical and Procedural Characteristics of Patients With and Without Access Site Bleeding
Characteristic
Access Site Bleeding
(n ¼ 124)*
Nonaccess Site Bleeding
(n ¼ 102)*
No Bleeding
(n ¼ 1,806) p Valuey p Valuez
Age, yrs 71.0  13.4 68.3  12.4 61.3  12.8 <0.001 <0.001
Female 86/124 (69.4) 37/102 (36.3) 489/1,806 (27.1) <0.001 0.043
BMI, kg/m2 24.2 (22.0–27.1) 24.9 (22.8–27.8) 26.2 (24.2–29.1) <0.001 0.009
History of
Diabetes 24/124 (19.4) 18/102 (17.6) 239/1,806 (13.2) 0.055 0.20
Hypertension 56/124 (45.2) 40/102 (39.2) 677/1,806 (37.5) 0.088 0.73
Dyslipidemia 19/124 (15.3) 11/102 (10.8) 435/1,806 (24.1) 0.026 0.002
Peripheral artery disease 19/124 (15.3) 13/102 (12.7) 106/1,806 (5.9) <0.001 0.005
Ischemic stroke or TIA 14/124 (11.3) 10/102 (9.8) 105/1,806 (5.8) 0.014 0.099
Malignancy 17/124 (13.7) 17/102 (16.7) 124/1,806 (6.9) 0.005 <0.001
Bleeding 10/124 (8.1) 10/102 (9.8) 66/1,806 (3.7) 0.015 0.002
Surgery <10 days 5/124 (4.0) 8/102 (7.8) 11/1,806 (0.6) <0.001 <0.001
Previous MI 20/124 (16.1) 18/102 (17.6) 216/1,806 (12.0) 0.17 0.088
Previous PCI 10/124 (8.1) 13/102 (12.7) 181/1,806 (10.0) 0.48 0.38
Previous CABG 2/124 (1.6) 5/102 (4.9) 38/1,806 (2.1) 0.71 0.064
Family history of CAD 40/124 (32.3) 24/102 (23.5) 690/1,806 (38.2) 0.19 0.003
Current smoker 41/124 (33.1) 37/102 (36.3) 810/1,806 (44.9) 0.011 0.090
Continued on the next page
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624follow-up of clinical outcome, including recurrent MI,
stroke, stent thrombosis, and bleeding, by reviewing in- and
outpatient charts in the tertiary PCI center and referring
hospitals between 2011 and 2012. For each patient, we
systematically checked inpatient charts of every hospital
admission for the occurrence of clinical events, including
hemorrhagic events and their location. Follow-up of clinical
events was censored at the actual date of chart review. Pa-
tients whose whereabouts could not be traced were consid-
ered lost to follow-up from the date of last known medical
contact. Follow-up information regarding vital status was
obtained from computerized long-term mortality records
from the National Death Index. If a patient could not be
identiﬁed in these records (e.g., foreign patients), censoring
was at the date of last contact. For the present analysis,
patients were censored at the date of death or at 1 year after
the index PCI, whichever came ﬁrst.
Study design. The study cohort consisted of all STEMI
patients included in our study database who were alive
at the end of the procedure. Bleeding was considered to
have occurred when the GUSTO (Global Utilization of
Streptokinase and Tissue Plasminogen Activator for
Occluded Arteries) severe or moderate bleeding criteria
were met (14). Bleeding was considered access site–related
if it originated at the PCI-related arterial puncture site or
in the retroperitoneal cavity in case of femoral access.
Bleeding originating at arterial puncture sites required for
achieving arterial access for an intra-aortic balloon pump
(IABP) or other left ventricular assist devices during the
index PCI were also deﬁned as ASB. All other bleeding
complications were considered nonaccess site-related. Asa sensitivity analysis, ASB and non-ASB were deﬁned
according to the Thrombolysis In Myocardial Infarction
major or minor criteria (15).
Cardiac mortality, recurrent MI, and stent thrombosis
(deﬁnite) were deﬁned according to the Academic Research
Consortium criteria (16). Stroke was deﬁned as an ir-
reversible neurological deﬁcit, as classiﬁed by the treating
neurologist, on the basis of supporting information, in-
cluding brain images and neurological evaluation.
Meta-analysis. We performed a computerized literature
search for the period 1980 to September 16, 2013, of the
PubMed and Embase databases, using search terms that
included “bleeding” or “hemorrhage” and “acute coronary
syndrome” or “percutaneous coronary intervention.” Study
selection was done by 2 independent reviewers (W.J.K.,
R.D.), and disagreement was resolved by a third reviewer
(J.P.S.H.). Citations were screened at the title/abstract
level and retrieved as full reports. Bibliographies of iden-
tiﬁed studies and relevant review articles were screened
for potentially suitable studies. Non-English articles, case
reports, reviews, and studies reporting duplicate data were
excluded.
To be included, studies had to include patients treated
with PCI and compared 1-year mortality of patients with
ASB and non-ASB occurring within 30 days after PCI. We
did not include studies that did not report adjusted HRs for
1-year mortality. Studies in which HRs for mortality were
not calculated in time-dependent Cox models were also
eligible for inclusion.
The ﬂow chart of the search strategy and selection of
studies is depicted in Figure 1. We identiﬁed 22 studies
Table 1. Continued
Characteristic
Access Site Bleeding
(n ¼ 124)*
Nonaccess Site Bleeding
(n ¼ 102)*
No Bleeding
(n ¼ 1,806) p Valuey p Valuez
Laboratory assays
Baseline WBC count, 103/mm3 11.7 (9.7–15.7) 13.4 (9.9–17.3) 11.1 (8.8–14.1) 0.005 <0.001
Baseline Hb, mmol/l 8.1 (7.1–8.8) 8.0 (7.0–8.9) 8.9 (8.3–9.5) <0.001 <0.001
Baseline thrombocyte count, 109/l 254 (207–305) 233 (184–310) 247 (208–291) 0.49 0.21
<150 7/124 (5.6) 10/101 (9.9) 61/1,787 (3.4)
150–400 111/124 (89.5) 86/101 (85.1) 1,665/1,787 (93.2) 0.29 0.002
>400 6/124 (4.8) 5/101 (5.0) 61/1,787 (3.4)
Baseline CrCl, ml/min/1.73 m2 59.1 (41.1–78.1) 63.3 (45.4–87.2) 94.8 (71.6–119.9) <0.001 <0.001
Mean aPTT, s 121 (94.2–143) 92.8 (66.8–134) 89.9 (71.1–112) <0.001 0.33
Procedural characteristics
Puncture site
Radial only 2/124 (1.6) 1/102 (1.0) 72/1,804 (4.0)
Femoral only 118/124 (95.2) 100/102 (98.0) 1,721/1,804 (95.4) 0.003 0.28
Other 4/124 (3.2) 1/102 (1.0) 11/1,804 (0.6)
Tortuous peripheral arteries 8/124 (6.5) 5/102 (4.9) 61/1,806 (3.4) 0.075 0.41
Calciﬁed peripheral arteries 8/124 (6.5) 2/102 (2.0) 31/1,806 (1.7) <0.001 0.85
Clopidogrel loading dose, mg 0.44 0.001
No loading dose 7/124 (5.6) 11/98 (11.2) 59/1,751 (3.4)
300 80/124 (64.5) 59/98 (60.2) 1118/1,751 (63.8)
600 37/124 (29.8) 28/98 (28.6) 563/1,751 (32.2)
Other 0/124 (0.44) 0/98 (0.0) 11/1,751 (0.6)
Cardiogenic shock 25/122 (20.5) 25/100 (25.0) 111/1,785 (6.2) <0.001 <0.001
IABP/LVAD 45/124 (36.3) 39/102 (38.2) 193/1,806 (10.7) <0.001 <0.001
Total ischemic time, min 240 (158–346) 192 (131–304) 178 (128–260) <0.001 0.20
Peak CK-MB release, mmol/l 321 (113–488) 175 (77.8–455) 213 (94.6–405) 0.010 0.64
GP IIb/IIIa inhibitor 46/124 (37.1) 32/102 (31.4) 501/1,806 (27.7) 0.025 0.43
Angiographic characteristics
IRA 0.13 0.85
LM/LAD 59/119 (56.7) 40/93 (43.0) 759/1,753 (43.3)
LCX/RCA 60/119 (50.4) 53/93 (57.0) 994/1,753 (56.7)
TIMI ﬂow
0/1 78/110 (70.9) 65/84 (77.4) 1,183/1,630 (72.6) 0.71 0.34
2/3 32/119 (29.1) 19/84 (22.6) 447/1,630 (27.4)
CTO in a non-IRA 22/118 (18.6) 18/97 (18.6) 232/1,727 (13.4) 0.11 0.15
MVD 57/118 (48.3) 46/97 (47.4) 623/1,727 (36.1) 0.008 0.024
Values are n (%), mean  SD, or median (interquartile range). *Patients who experienced both access and nonaccess site bleeding were counted in both access and nonaccess site bleeding groups. yp
Value for access site bleeding versus no bleeding. zp Value for nonaccess site bleeding versus no bleeding.
aPTT ¼ activated partial thromboplastin time; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CK-MB ¼ creatine kinase-myocardial band;
CrCl ¼ creatinine clearance; CTO ¼ chronic total occlusion; GP ¼ glycoprotein; Hb ¼ hemoglobin; IABP ¼ intra-aortic balloon pump; IRA ¼ infarct-related artery; LAD ¼ left anterior descending artery;
LM ¼ left main artery; LVAD ¼ left ventricular assist device; MI ¼ myocardial infarction; MVD ¼ multivessel disease; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; RCx ¼ ramus
circumﬂexus; TIA ¼ transient ischemic attack; TIMI ¼ Thrombolysis In Myocardial Infarction; WBC ¼ white blood cell.
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625potentially suitable for inclusion in our meta-analysis; 2 of
these were excluded because they reported duplicate data,
and 14 studies were excluded because 1-year mortality after
ASB and non-ASB was not reported. Of the 6 studies
reporting 1-year mortality after ASB and non-ASB, 2 were
removed because adjusted HRs for 1-year mortality were not
reported. Finally, we included the results of the present study
in our meta-analysis. Therefore, a total of 5 studies were
included in our meta-analysis of the prognostic value of ASB
and non-ASB.Statistical analysis. To investigate the occurrence of clin-
ical outcomes (cardiac and noncardiac mortality, recurrent
MI, stent thrombosis, and stroke) after ASB and non-
ASB, the following analyses were designed. The rela-
tionship between the occurrence of ASB and non-ASB
within 30 days and subsequent 1-year outcomes compared
with patients without bleeding was investigated by
inserting these events simultaneously as time-dependent
variables in 2 sets of Cox proportional hazards models for
each clinical outcome measure: unadjusted models and
Figure 2. Cumulative Mortality According to Access Site–Related and
Nonaccess Site–Related Bleeding
Shown are Kaplan-Meier curves for mortality after the occurrence of access
site–related bleeding or nonaccess site–related bleeding within 30 days after
primary percutaneous coronary intervention. Zero time point is time of the
bleeding event. Patients who experienced both access and nonaccess site
bleeding were counted in both access and nonaccess site bleeding groups.
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626models adjusted for relevant predictors of these clinical
outcomes. Relevant predictors were identiﬁed by perform-
ing stepwise backward-selection Cox regression analyses.
Entry criterion was set at p < 0.05 and exit criterion was set
at p ¼ 0.10.
Normally distributed continuous variables are reported as
the mean with SD and compared with the Student t test;
skewed distributed variables are presented as the median
with interquartile range (IQR) and compared with the
Wilcoxon rank sum test. Categorical variables are presented
as proportions and compared with the chi-square test. All
tests were 2-sided, and a p < 0.05 was considered statisti-
cally signiﬁcant.
We performed a meta-analysis of adjusted HRs for 1-year
mortality according to ASB and non-ASB, using the generic
inverse variance method (17). The heterogeneity across
studies was assessed using the I2 statistic. Analyses were
performed with Statistical Package for Social Sciences
software (SPSS version 18.0, Chicago, Illinois) and Review
Manager (RevMan) (Version 5.2., The Nordic Cochrane
Centre, Copenhagen, Denmark).
Results
Of the 3,472 STEMI patients treated with primary PCI
in our institution between January 1, 2003 and July 31,
2008, we collected follow-up for 2,009 patients. Of these
2,009 patients, 2,002 were alive at the end of the procedure.
Baseline, procedural, and angiographic characteristics for
patients included and excluded in the analysis are given in
Online Table 1. Patients included in the analysis more
often presented in cardiogenic shock and were more
often treated with an IABP. One-year mortality was
complete in 99.8% (1997/2002) of patients included in the
analysis and 99.1% (1,457/1,470) of patients excluded
from the analysis. One-year mortality was 11.8% in pa-
tients included in the analysis, whereas mortality was 10.3%
in patients excluded (p ¼ 0.22).
Seventy-four patients underwent PCI via radial access,
1,910 patients underwent PCI via the femoral artery, and
the remaining 16 patients underwent PCI via a combi-
nation of femoral or radial access or an access site other
than the femoral or radial access site. One-year clinical
follow-up was complete for 99% of patients (1981/2002).
In total, 196 patients (9.9%) experienced GUSTO severe
or moderate bleeding within 30 days of follow-up. The
distribution of the location of bleeding events is shown in
Online Table 2. Of the 196 patients who experienced
GUSTO severe or moderate bleeding within 30 days, 52%
(n ¼ 102) of patients experienced non-ASB, 63.2%
(n ¼ 124) of patients experienced bleeding originating at
an arterial puncture site (30 patients experienced both). In
the ﬁrst 30 days after PPCI, 7 patients experienced a fatal
bleeding event. Five of these events had a hemopericardialorigin, 1 was coronary artery bypass graft related, and 1
was located in the retroperitoneal cavity. Baseline clinical
and procedural characteristics of patients with ASB or
non-ASB compared with patients without bleeding are
given in Table 1. Patients with ASB and non-ASB had a
higher baseline risk proﬁle. Compared with patients
without bleeding, they typically had more severe athero-
sclerosis, a higher leukocyte count, and lower creatinine
clearance on presentation; more often had cardiogenic
shock; and more often required IABP treatment for he-
modynamic support.
Prognostic value of ASB and non-ASB. Figure 2 displays
Kaplan-Meier curves for 1-year mortality of patients with
ASB and non-ASB. Table 2 displays the unadjusted and
adjusted associations between ASB and non-ASB that
met the GUSTO severe or moderate bleeding criteria
and 1-year outcomes. On multivariable analysis, ASB was
not associated with a higher risk of recurrent MI, stroke,
stent thrombosis, and cardiac and all-cause mortality.
Conversely, non-ASB was associated with a 3-fold higher
risk of stent thrombosis and cardiac and all-cause mortality
after adjustment for confounders. Online Table 3 provides
the unadjusted and adjusted relationships between ASB
and non-ASB that met the Thrombolysis In Myocardial
Infarction major or minor bleeding criteria and 1-year
outcomes.
Impact of ASB and non-ASB on antithrombotic therapy.
Patients who experienced non-ASB during the index hos-
pital admission were admitted for a median duration of
18 days (interquartile range [IQR]: 11 to 24 days) compared
Table 2. Unadjusted and Adjusted Hazard Ratios for 1-Year Clinical Outcome According to Bleeding Status
No. of Patients
Unadjusted* Adjustedy
HR 95% CI p Value HR 95% CI p Value
All-cause mortality
No ASB 203 1.00 d d 1.00 d d
After ASB 32/124 1.73 1.16–2.58 0.008 1.03 0.69–1.53 0.89
No non-ASB 193 1.00 d d 1.00 d d
After non-ASB 42/102 5.77 4.03–8.26 <0.001 2.77 1.92–3.99 <0.001
Cardiac mortality
No ASB 173 1.00 d d 1.00 d d
After ASB 28/124 1.73 1.13–2.67 0.012 0.97 0.64–1.49 0.90
No non-ASB 164 1.00 d d 1.00 d d
After non-ASB 37/102 6.02 4.09–8.84 <0.001 3.15 2.14–4.66 <0.001
Noncardiac mortality
No ASB 30 1.00 d d 1.00 d d
After ASB 4/124 1.65 0.55–4.94 0.38 1.04 0.32–3.37 0.95
No non-ASB 29 1.00 d d 1.00 d d
After non-ASB 5/102 4.44 1.63–12.1 0.003 2.57 0.92–7.22 0.072
Recurrent myocardial infarction
No ASB 134 1.00 d d 1.00 d d
After ASB 15/124 1.71 0.99–2.97 0.057 1.16 0.66–2.02 0.64
No non-ASB 139 1.00 d d 1.00 d d
After non-ASB 10/102 2.08 1.10–3.93 0.024 1.46 0.77–2.76 0.24
Stent thrombosis
No ASB 64 1.00 d d 1.00 d d
After ASB 2/124 0.43 0.10–1.83 0.25 0.55 0.13–2.36 0.42
No non-ASB 61 1.00 d d 1.00 d d
After non-ASB 5/102 3.17 1.25–8.09 0.016 3.10 1.19–8.11 0.021
Stroke
No ASB 35 1.00 d d 1.00 d d
After ASB 2/124 1.22 0.29–5.06 0.79 0.47 0.11–2.01 0.31
No non-ASB 37 1.00 d d 1.00 d d
After non-ASB 0/102 d d d d d d
The HR for all-cause mortality was adjusted for age, history of hypertension, family history of coronary artery disease, current smoking, history of
bleeding, history of malignant disease, creatinine clearance, thrombocyte count, leukocyte count, baseline hemoglobin, percutaneous coronary
intervention access site, cardiogenic shock, intra-aortic balloon pump, multivessel disease, the presence of a chronic total occlusion, infarct-
related artery, and total ischemic time. A list of the variables included in the remaining multivariable models can be found in the Online Appendix.
*Unadjusted HRs and corresponding CIs were calculated using Cox proportional hazard models using bleeding status as a time-dependent
covariate. yAdjusted HRs and corresponding CIs were calculated using Cox proportional hazard models using bleeding status as a time-
dependent covariate.
ASB ¼ access site bleeding; CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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627with 13 days (IQR: 7 to 21 days) in patients who experi-
enced ASB and 5 days (IQR: 3 to 8 days) in those who did
not experience any bleeding during the index admission
(p < 0.001). Other treatment aspects associated with ASB
and non-ASB are given in Table 3. Figure 3 displays the
rates of discontinuation of antiplatelet therapy according to
bleeding source. Antiplatelet agents were most often dis-
continued indeﬁnitely in patients with non-ASB. Of the
124 patients with ASB, 3 experienced a stent thrombosis
within the following year. Conversely, of the 104 patients
with non-ASB, 5 experienced a stent thrombosis within the
following year. In 1 of these patients, antiplatelet therapywas discontinued indeﬁnitely after the preceding bleeding
event.
Meta-analysis. Including the present study, there are 5
studies reporting adjusted HRs for mortality after ASB
and non-ASB, including a total of 495,630 patients (7–10).
Two studies included patients undergoing elective PCI or
PCI for acute coronary syndrome (7,9). The study by Rao
et al. (9) excluded patients younger than 65 years of age.
Two studies including the present study were conducted in
STEMI (8). Finally, 1 study was performed in elective PCI
and non–ST-segment elevation acute coronary syndrome
only (10). A forest plot of the adjusted HRs for 1-year
Table 3. Characteristics of Bleeding Episodes by Access and
Nonaccess Site Bleeding
Characteristics
Access Site
Bleeding
(n ¼ 124)
Nonaccess Site
Bleeding
(n ¼ 102) p Value
Blood transfusions, U 3 (2–4) 3 (2–7) 0.048
Hemoglobin decrease, mmol/l 2.9 (2.2–3.9) 2.6 (1.7–3.9) 0.076
Immediate discontinuation of
antithrombotic therapy because
of bleeding event
35/124 (28.2) 44/102 (43.1) 0.019
Diagnostic radiological procedure
related to bleeding
65/124 (52.4) 36/102 (35.3) 0.010
Surgery related to bleeding 10/124 (8.1) 21/102 (20.6) 0.006
Values are median (interquartile range) or n (%). Patients who experienced both access and
nonaccess site bleeding were counted in both access and nonaccess site bleeding groups.
Figure 3. Discontinuation of Antiplatelet Therapy Related to Bleeding
The bars indicate the percentage of patients with bleeding in whom anti-
platelet therapy was discontinued indeﬁnitely after a bleeding event. Patients
who experienced both access and nonaccess site bleeding were counted in
both access and nonaccess site bleeding groups.
Kikkert et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 6 , 2 0 1 4
Access Site and Nonaccess Site Bleeding in STEMI J U N E 2 0 1 4 : 6 2 2 – 3 0
628mortality is shown after ASB (Fig. 4A) and non-ASB
(Fig. 4B). Both ASB and non-ASB are signiﬁcantly asso-
ciated with 1-year mortality. The degree of risk, however, is
dependent on the source of bleeding; the adjusted risk of
1-year mortality is higher in patients with non-ASB com-
pared with patients with ASB (combined HRs of 1.66 and
1.21, respectively).
Discussion
The main ﬁndings of our study are that in 2,002 STEMI
patients, bleeding complications arising at the arterial
puncture site, regardless of the bleeding deﬁnition applied,
were not associated with an increased risk of mortality,
recurrent MI, stent thrombosis, or stroke. By contrast, non-
ASB was associated with a 3-fold higher risk of cardiac and
all-cause mortality within 1 year after PPCI. A novel
ﬁnding that provides further insight into the difference in
prognostic value was that non-ASB was associated with
higher rates of discontinuation of antiplatelet therapy and
stent thrombosis. In a meta-analysis including 5 studies
investigating the risk of 1-year mortality in patients with
ASB and non-ASB, we found that both ASB and non-
ASB were signiﬁcantly associated with 1-year mortality.
Non-ASB was associated with the strongest risk of 1-year
mortality.
Difference in prognostic value. On univariate analysis, ASB
and non-ASB were associated with a higher risk of 1-year
mortality. After multivariable adjustment, ASB was no
longer associated with a higher risk of mortality, whereas
non-ASB was associated with a 3-fold higher risk of mor-
tality. This suggests that the higher mortality in patients
with ASB can be explained by factors associated with high
mortality, such as cardiogenic shock, acute renal insufﬁ-
ciency, and multivessel disease. Our observation that non-
ASB is associated with a worse prognosis than ASB is
consistent with previous studies. In our meta-analysis, wefound that non-ASB was associated with a greater risk of
1-year mortality than ASB.
Several factors may have contributed to the difference in
prognostic value between ASB and non-ASB. First, ASB
was less often associated with a discontinuation in antith-
rombotic therapy, which is known to increase the risk of
stent thrombosis and recurrent MI (18). Indeed, we
observed a greater risk of stent thrombosis within 1 year in
patients with a non-ASB. Second, compared with ASB,
non-ASB occurs in anatomically more remote areas of the
body, resulting in a greater delay between the moment of
onset of bleeding and diagnosis. Moreover, non-ASB is less
easily accessible to interventions directed at gaining imme-
diate control of the bleeding. Third, non-ASB may unveil
previously concealed ominous comorbidities, which are by
themselves correlates of a worse outcome, such as an un-
known malignancy. Finally, we hypothesize that non-ASB,
more than ASB, may be a marker of unmeasured con-
founders or frailty.
Prognostic value of non-ASB. In accordance with previous
studies, the risk of 1-year mortality was greatest in patients
with non-ASB. This is a signiﬁcant ﬁnding given the fact
that half of all bleeding events originated at a location other
than the access site. A number of mechanisms may be
responsible for the relationship between non-ASB and
1-year mortality. First, non-ASB was associated with a
discontinuation of aspirin or clopidogrel in 13.5% of cases.
Discontinuation of antiplatelet therapy is associated with a
greater risk of stent thrombosis and recurrent MI (18).
Second, bleeding may result in anemia and impaired oxygen
delivery to vital end organs such as the brain, kidneys, and
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Figure 4. Meta-analysis of Hazard Ratios for Mortality Stratiﬁed by Bleeding Source
(A) The meta-analysis of adjusted hazard ratios (HRs) for 1-year mortality of access site–related bleeding. (B) The meta-analysis of adjusted hazard ratios for 1-year
mortality of nonaccess site–related bleeding. ACS ¼ acute coronary syndrome; CI ¼ conﬁdence interval; NSTE-ACS ¼ non–ST-segment elevation–acute coronary
syndrome; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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629myocardium. In patients with multivessel coronary artery
disease and/or a poor systolic function, impaired oxygen
delivery to the myocardium may deteriorate myocardial
function and result in hemodynamic compromise and car-
diac death. Third, erythropoietin synthesis in response to
anemia may induce a prothrombotic state by causing platelet
activation and increased production of plasminogen activa-
tor inhibitor 1 (19,20). Fourth, non-ASB required blood
transfusions, which have been associated with mortality (21).
Finally, non-ASB may merely be a marker of unmeasured
comorbidities and frailty.
Study limitations. The patients included in the present
analysis were selected from a series of consecutive STEMI
patients on the basis of the availability of an aPTT mea-
surement. We did not collect information on bleeding and
ischemic outcomes in patients without aPTT measurements.
This might have introduced selection bias. Although pa-
tients included in our analysis more often presented in
cardiogenic shock and were more often treated with IABP,
there was no difference in 1-year mortality between patients
included and excluded in the analysis. Moreover, the pri-
mary analyses of this study are based on HRs, which is a
proportional effect measure. Therefore, we believe it is un-
likely that the selection of patients has inﬂuenced the esti-
mates of the HRs provided in Table 2. The data presented
in the present analysis pertain to selected STEMI patients
undergoing PPCI at a single center. Therefore, our resultsmight not be applicable to a general STEMI population.
However, the baseline and procedural characteristics of pa-
tients included in the study were representative of a typical
European STEMI cohort.
Conclusions
In a contemporary cohort of STEMI patients, ASB was not
associated with an increased risk of mortality and recurrent
ischemic events, whereas non-ASB was associated with an
increased risk of mortality and stent thrombosis. These re-
sults taken together with the results of 4 previous studies in
almost 500,000 patients indicate a greater hazard of subse-
quent mortality in patients with non-ASB. Our study sup-
ports the need to develop treatment strategies that diminish
non-ASB.
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